Combination partners with BsAbs in actively recruiting clinical trials
| Disease . | BsAb . | Drug partner . | Target . | Clinical trial number . |
|---|---|---|---|---|
| DLBCL | Mosunetuzumab | Loncastuximabtesirine | CD19 | NCT05672251 |
| DLBCL | Mosunetuzumab | Chemotherapy | NCT06249191 | |
| DLBCL, FL | Mosunetuzumab | Polatuzumab vedotin | CD79b | NCT06015880 NCT06453044 |
| DLBCL | Epcoritamab | Lenalidomide | Cereblon | NCT05660967 |
| MCL | Glofitamab | Venetoclax, obinutuzumab, lenalidomide | BCL-2 CD20 Cereblon | NCT05861050 |
| DLBCL | Epcoritamab | Ibrutinib | Btk | NCT06536049 |
| MCL | Glofitamab | Pirtobrutinib | Btk | NCT06252675 |
| FL | Epcoritamab | Tazemetostat | EZH2 | NCT06575686 |
| MZL | Glofitamab | Obinutuzumab | CD20 | NCT05783596 |
| Disease . | BsAb . | Drug partner . | Target . | Clinical trial number . |
|---|---|---|---|---|
| DLBCL | Mosunetuzumab | Loncastuximabtesirine | CD19 | NCT05672251 |
| DLBCL | Mosunetuzumab | Chemotherapy | NCT06249191 | |
| DLBCL, FL | Mosunetuzumab | Polatuzumab vedotin | CD79b | NCT06015880 NCT06453044 |
| DLBCL | Epcoritamab | Lenalidomide | Cereblon | NCT05660967 |
| MCL | Glofitamab | Venetoclax, obinutuzumab, lenalidomide | BCL-2 CD20 Cereblon | NCT05861050 |
| DLBCL | Epcoritamab | Ibrutinib | Btk | NCT06536049 |
| MCL | Glofitamab | Pirtobrutinib | Btk | NCT06252675 |
| FL | Epcoritamab | Tazemetostat | EZH2 | NCT06575686 |
| MZL | Glofitamab | Obinutuzumab | CD20 | NCT05783596 |
FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma.